ASH 2024 | QoL outcomes for patients with R/R CLL treated with ibrutinib plus venetoclax in HOVON-141 / VIsion

Yes, so a couple of years ago we conducted the HOVON 141 study, also called the VISION study. And it’s in the relapsed/refractory CLL patients. And these patients got IV treatment, ibrutinib and venetoclax treatments. And after a year we looked if they reached MRD negativity. And if they reached MRD negativity, two-thirds of patients could stop treatment. and one-third of patients had to continue ibrutinib. The patients who still showed MRD positivity had to continue ibrutinib treatment. And we looked at the quality of life in these patients because we know the results of this trial with regard to MRD negativity, progression-free and overall survival, and it was quite good. But the question is, if you stop ibrutinib treatment, does it improve quality of life? And does ibrutinib and venetoclax treatment in all these patients improve quality of life? And what we saw is that after the first year of IV treatment, the global health status improves very much, even to levels which are really clinically relevant for our patients. Like fatigue goes down and worries about their illness goes down, but in the first year they have more complaints of diarrhea. And after this year all these levels remain stable so all the patients remained on a better global health status than before treatments. And if you look at the arms which continue treatment or stop treatments we didn’t have enough power to really statistically compare those arms but if you look at the numbers the numbers with a good global health status is numerically better in the patients who stop ibrutinib versus those who continue ibrutinib. And this talk was given by one of our postdocs Laura Eurelings yesterday.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.